The IL-23 inhibitor from AbbVie indicated for the treatment of moderately to severely active Crohn's disease (CD) in adults.¹

SKYRIZI vs STELARA^® (ustekinumab)
RESULTS FROM A HEAD-TO-HEAD STUDY

ENDPOINTS IN ADVANCE, MOTIVATE AND FORTIFY¹

All p-values are SKYRIZI treatment arms vs. placebo.

Placebo (Induction Responders): Patients who achieved CDAI clinical response (CR-100)^‡ to SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.

STUDY DESIGNS:

ADVANCE (N=850) and MOTIVATE (N=569) Induction studies were 12-week, randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI in patients with moderately to severely active Crohn’s disease^§ who demonstrated prior treatment failure to conventional and/or biologic treatment.³ Patients received an IV infusion of SKYRIZI 600 mg (recommended dose), risankizumab-rzaa 1200 mg^|| or placebo at Weeks 0, 4, and 8.¹

FORTIFY (N=382) Maintenance study was a 52-week study that evaluated the efficacy and safety of SKYRIZI in patients who achieved clinical response (decrease in CDAI ≥100)^‡ from SKYRIZI induction in the ADVANCE and MOTIVATE studies. Patients were randomized to SKYRIZI 180 mg SC, SKYRIZI 360 mg SC, or placebo at Week 12 and every 8 weeks thereafter.¹

CROHN’S DISEASE THERAPIES EVALUATED
IN AN OPEN-LABEL ASSESSOR BLINDED HEAD-TO-HEAD TRIAL^2,3

First Approved Crohn's Disease Therapy: Ste vs Sky

PRIMARY ENDPOINTS EVALUATED:

Non-Inferiority Endpoint: CLINICAL REMISSION (CDAI <150) AT WEEK 24*
Superiority Endpoint: ENDOSCOPIC REMISSION^† (SES-CD ≤4) AT WEEK 48^‡

*The percentage of subjects who met clinical remission at Week 24. Statistical requirement for non-inferiority achieved with ~50% of study population.

^†Endoscopic remission: SES-CD ≤4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable, as scored by a
central reviewer.

^‡The percentage of subjects who met endoscopic remission at Week 48.

Study Design Intro: SEQUENCE was a Phase 3, multicenter, randomized, open-label, efficacy assessment-blinded^§ study of SKYRIZI (n=255) compared to STELARA (ustekinumab)^|| (n=265) for the treatment of adult patients with moderate to severe Crohn's disease who have failed anti-TNF therapy. Eligible patients were randomized (1:1) to receive either SKYRIZI (600 mg IV to 360 mg SC) or STELARA (weight-based^¶ IV to 90 mg SC). After induction dosing was completed, patients remained on their respective therapy throughout the duration of the maintenance period (treat-through study design). No dose escalation allowed throughout the trial.

Dosing: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

^§The investigator and site personnel were blinded to the results of the clinical outcomes (CDAI) and endoscopies were centrally read with assessors blinded
to study drug.

^||Active Comparator: 31 patients received US approved ustekinumab. All other patients received European Union approved ustekinumab. The comparability between US and Non US approved ustekinumab has not been established.

^¶Baseline Stelara IV dose is weight based: ≤55 kg: 260 mg; >55 kg to 85 kg: 390 mg; or >85 kg: 520 mg.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

PRIMARY ENDPOINTS

HEAD-TO-HEAD TRIAL: PRIMARY ENDPOINTS (NRI-MI)^2,3

SEQUENCE was a Phase 3, multicenter, randomized, open-label, efficacy assessment-blinded^* head-to-head study comparing
SKYRIZI and STELARA (ustekinumab) in adult patients with moderate to severe Crohn's disease who have failed anti-TNF therapy.

~2X MORE PATIENTS on SKYRIZI met Endoscopic Remission vs STELARA at Week 48

Patients at baseline had an average disease duration of ~9 years and average SES-CD
score of 14

SKYRIZI DEMONSTRATED SYMPTOM RELIEF AS MEASURED BY CLINICAL REMISSION AT WEEK 24

~2X MORE PATIENTS on SKYRIZI Met Endoscopic Remission vs STELARA at Week 48

Patients at baseline had an average disease duration of ~9 years and average SES-CD
score of 14

SKYRIZI MET SYMPTOM RELIEF AS MEASURED BY CLINICAL REMISSION AT WEEK 24

Data Limitation: The open-label nature of this study may have introduced bias and influenced these results.

Endoscopic remission outcome was unavailable for 12.9% (33/255) for SKYRIZI patients and 26% (69/265) for STELARA patients.

Dosing: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

^*The investigator and site personnel were blinded to the results of the clinical outcomes (CDAI) and endoscopies were centrally read with assessors blinded to study drug.

^†Active Comparator: 31 patients received US approved ustekinumab. All other patients received European Union approved ustekinumab. The comparability between US and Non US approved ustekinumab has not been established.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

ENDOSCOPIC DATA

Endoscopic Response Endoscopic Response

Endoscopic Remission Endoscopic Remission

STEROID-FREE ENDOSCOPIC REMISSION STEROID-FREE ENDOSCOPIC REMISSION

ENDOSCOPIC OUTCOMES^2,3

SEQUENCE was a Phase 3, multicenter, randomized, open-label, efficacy assessment-blinded^* head-to-head study comparing SKYRIZI and STELARA (ustekinumab) in adult patients with moderate to severe Crohn's disease who have failed anti-TNF therapy.

Endoscopic Response at Week 24 and Week 48 (Ranked Secondary Superiority Endpoints, NRI-MI)

ADVANCE: Endoscopic response at Week 12: Bio-naïve subgroup: 50% in SKYRIZI 600 mg IV (n=141) vs 13% in placebo (n=78). Biologic failure subgroup: 33% in SKYRIZI 600 mg IV (n=195) vs 11% in placebo (n=97)

More Patients on SKYRIZI MET Endoscopic Response vs STELARA at  Weeks 24 and 48

DATA LIMITATION: The open-label nature of this study may have introduced bias and influenced these results.

DOSING: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

^*Endoscopies were centrally read with assessors blinded to study drug.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

ENDOSCOPIC OUTCOMES^2,3

Endoscopic Remission at Week 48 (Primary Superiority Endpoint, NRI-MI)

FORTIFY: Endoscopic response at Week 52: Bio-naïve subgroup: 59% in SKYRIZI 360 mg SC (n=34) vs 23% in placebo (induction responders) (n=31). Biologic failure subgroup: 44% in SKYRIZI 360 mg SC (n=83) vs 21% in placebo (induction responders) (n=99)

~2x More Patients on SKYRIZI MET Endoscopic Remission vs Stelara at Week 48

PATIENTS AT BASELINE HAD AN AVERAGE DISEASE DURATION OF ~9 YEARS AND AVERAGE SES-CD SCORE OF 14

~2x More Patients on SKYRIZI MET Endoscopic Remission vs Stelara at Week 48

PATIENTS AT BASELINE HAD AN AVERAGE DISEASE DURATION OF ~9 YEARS AND AVERAGE SES-CD SCORE OF 14

Data Limitation: The open-label nature of this study may have introduced bias and influenced these results.

Endoscopic remission outcome was unavailable for 12.9% (33/255) for SKYRIZI patients and 26% (69/265) for STELARA patients.

Dosing: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

^*Endoscopies were centrally read with assessors blinded to study drug.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

ENDOSCOPIC OUTCOMES^2,3

Steroid-Free Endoscopic Remission at Week 48 (Ranked Secondary Superiority Endpoint, NRI-MI)

~2x More Patients on SKYRIZI met Endoscopic Remission without Steroids (Steroid-Free Endoscopic Remission) vs STELARA at Week 48

IN THE SEQUENCE TRIAL, 71 (27%) AND 58 (23%) PATIENTS WERE TAKING CORTICOSTEROID AT BASELINE IN THE STELARA AND SKYRIZI ARMS, RESPECTIVELY.

~2x More Patients on SKYRIZI MET Endoscopic Remission without Steroids (Steroid-Free Endoscopic Remission) vs STELARA at Week 48

IN THE SEQUENCE TRIAL, 71 (27%) AND 58 (23%) PATIENTS WERE TAKING CORTICOSTEROID AT BASELINE IN THE STELARA AND SKYRIZI ARMS, RESPECTIVELY.

Data Limitation: The open-label nature of this study may have introduced bias and influenced these results.

Steroid Free Endoscopic remission outcome was unavailable for 12.9% (33/255) for SKYRIZI patients and 26% (69/265) for STELARA patients.

Dosing: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

Steroid-free Endoscopic Remission: Total population of patients who achieved endoscopic remission, defined as SES-CD ≤4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable, as scored by a central reviewer, who also did not receive a steroid at Week 48.

^*Endoscopies were centrally read with assessors blinded to study drug.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

CLINICAL REMISSION DATA

SYMPTOM RELIEF DATA^2,3

Clinical Remission at Week 24 and Week 48 (NRI-MI)

SKYRIZI MET SYMPTOM RELIEF AS MEASURED BY CLINICAL REMISSION AT WEEK 24 AND WEEK 48

Data Limitation: The open-label nature of this study may have introduced bias and influenced these results.

Dosing: The lowest effective dosage for SKYRIZI should be used to maintain therapeutic response. The comparative effectiveness of SKYRIZI 180 mg is unknown, as it was not evaluated in this study.

^*The investigator and site personnel were blinded to the results of the clinical outcomes (CDAI).

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

SAFETY DATA

SAFETY PROFILE: EVALUATION THROUGH WEEK 48^2,3

SEQUENCE was a Phase 3, multicenter, randomized, open-label, study of SKYRIZI and STELARA (ustekinumab) in adult patients with moderate to severe Crohn's disease who have failed anti-TNF therapy.

TREATMENT EMERGENT ADVERSE EVENTS THROUGH WEEK 48	STELARA^® (ustekinumab)^*	SKYRIZI
	(N=265, PYs=269.9) % (E/100 PYs)	(N=262, PYs=257.6) % (E/100 PYs)
Any AE	82.6 (282.7)	85.1 (341.2)
Serious AE	17.4 (23.7)	10.3 (14.0)
AE leading to discontinuation of study drug	4.9 (5.2)	3.8 (3.9)
Death	0	0
Infections	44.5 (62.6)	53.8 (90.4)
Serious infection	4.2 (5.2)	3.1 (3.9)
Opportunistic infection (excluding TB/Herpes Zoster)	0	0.4 (0.4)
Malignant tumors	0.4 (0.4)	0.4 (0.4)
Adjudicated MACE^a	0.4 (0.4)	0
Active TB	0	0
Herpes Zoster	0.4 (0.4)	0.4 (0.4)
Serious hypersensitivity	0	0
Adjudicated anaphylactic reaction	0	0
Hepatic events	5.3 (8.5)	6.9 (10.1)
Injection site reactions	2.3 (3.0)	1.9 (1.9)

For the safety population, 7 patients randomized to SKYRIZI received 1200 mg IV and/or 180 mg SC and were included only in the safety analysis.
Safety Data presented includes all patients who received at least 1 dose of study drug.

^*Active Comparator: 31 patients received US approved ustekinumab. All other patients received European Union approved ustekinumab. The comparability between US and Non US approved ustekinumab has not been established.

®STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.

The safety profile of SKYRIZI was generally consistent
with previously reported studies and as described in the
full Prescribing Information.

The Safety Rates observed in clinical trials may not reflect
clinical practice.

HAVE YOU SEEN
THE PATIENT CASE STUDIES?

DISCOVER PATIENT CASES

DO YOU KNOW ABOUT
SKYRIZI'S ESTABLISHED
SAFETY PROFILE?

EXPLORE SAFETY

Treatment Emergent Adverse Events (TEAEs)	STELARA ^® (ustekinumab)^† N=265 n (%)	SKYRIZI N=262 n (%)
COVID-19	66 (24.9)	73 (27.9)
Headache	12 (4.5)	18 (6.9)
Crohn’s Disease	39 (14.7)	17 (6.5)
Nasopharyngitis	9 (3.4)	16 (6.1)
Pyrexia	7 (2.6)	16 (6.1)
Upper respiratory tract infection	8 (3.0)	14 (5.3)
Arthralgia	22 (8.3)	13 (5.0)
Anemia	15 (5.7)	12 (4.6)

	ADVANCE N=850
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 12
DURATION	12-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, corticosteroids, and Crohn's-related antibiotics
DOSING	IV infusion of SKYRIZI 600 mg, risankizumab-rzaa 1200 mg,^c or placebo, at Weeks 0, 4, and 8
INCLUSION CRITERIA	Moderately to severely active Crohn's disease: CDAI 220-450 Average daily SF ≥4 or APS ≥2 SES-CD ≥6 (≥4 for isolated ileitis), exluding the narrowing component 16-80 years old Advanced therapy naïve^d or advanced therapy failure^e

	MOTIVATE N=569
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 12
DURATION	12-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, corticosteroids, and Crohn's-related antibiotics
DOSING	IV infusion of SKYRIZI 600 mg, risankizumab-rzaa 1200 mg,^c or placebo, at Weeks 0, 4, and 8
INCLUSION CRITERIA	Moderately to severely active Crohn's disease: CDAI 220-450 Average daily SF ≥4 or APS ≥2 SES-CD ≥6 (≥4 for isolated ileitis), exluding the narrowing component 16-80 years old Advanced therapy failure^e

	FORTIFY N=382
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 52
DURATION	52-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, and Crohn's-related antibiotics Patients taking corticosteroids at the start of FORTIFY had their therapy tapered
DOSING	Subcutaneous injection of SKYRIZI 180 mg, SKYRIZI 360 mg, or placebo starting at Week 12 and every 8 weeks after
INCLUSION CRITERIA	Moderately to severely active Crohn's disease: Entry and completion of ADVANCE or MOTIVATE. Completion includes the final endoscopy of ADVANCE or MOTIVATE Achieved Clinical Response^f in ADVANCE or MOTIVATE studies

FORTIFY		Placebo (Induction Responder) N=130	SKYRIZI 180 mg SC N=135	SKYRIZI 360 mg SC N=117
BASELINE OF INDUCTION (ADVANCE, MOTIVATE)
	Male, n (%)	72 (55.4)	62 (45.9)	67 (57.3)
	Age (years), mean (SD)	38.0 (12.8)	39.2 (14.7)	36.2 (12.6)
	Disease duration (years), mean (SD)	9.6 (8.2)	10.6 (10.2)	8.6 (7.1)
	Disease location
	lleal only, n (%)	18 (14)	12 (9)	13 (11)
	Colonic only, n (%)	49 (38)	63 (47)	52 (44)
	lleal-colonic, n (%)	63 (49)	60 (44)	52 (44)
	Baseline immunomodulatorimmuno- modulator use, n (%)	33 (25.4)	37 (27.4)	34 (29.1)
	Baseline steroid use, n (%)	40 (30.8)	47 (34.8)	36 (30.8)
	Advanced therapy*-failure history
	0, n (%)	31 (23.8)	40 (29.6)	34 (29.1)
	1, n (%)	49 (37.7)	34 (25.2)	42 (35.9)
	>1, n (%)	50 (38.5)	61 (45.2)	41 (35.0)
	Baseline CDAI, mean (SD)	314.2 (64.2)	327.6 (68.2)	316.2 (59.6)
	Baseline SES-CD, mean (SD)	14.1 (7.1)	14.9 (7.2)	14.3 (7.0)
	Baseline SF, mean (SD)	5.8 (2.7)	6.2 (3.1)	5.9 (2.7)
	Baseline APS, mean (SD)	1.9 (0.5)	2.0 (0.4)	1.9 (0.5)
	Baseline FCP (mg/kg), median (min,max)	904.0 (30, 11378)	1666.0 (30, 28800)	1622.0 (30, 14649)
	Baseline hs-CRP (mg/L), median (min,max)	7.9 (0.3, 181)	8.7 (0.4, 151)	10.6 (0.3, 129)

Week 0 of Maintenance
	CDAI at Week 0, mean (SD)	111.6 (69.5)	117.6 (66.8)	125.4 (62.7)
	SES-CD at Week 0, mean (SD)	7.3 (6.4)	7.8 (6.4)	8.3 (7.3)
	SF at Week 0, mean (SD)	1.4 (1.7)	2.1 (1.9)	1.9 (1.7)
	APS at Week 0, mean (SD)	0.6 (0.5)	0.6 (0.5)	0.6 (0.5)
	FCP (mg/kg) at Week 0, median (min,max)	300.0 (30, 22912)	361 (30, 28800)	485.5 (30, 14804)
	hs-CRP (mg/L) at Week 0, median (min,max)	3.6 (0, 42)	3.7 (0, 48)	4.0 (0, 258)

SKYRIZI vs STELARA^® (ustekinumab)
RESULTS FROM A HEAD-TO-HEAD STUDY

ENDPOINTS IN ADVANCE, MOTIVATE AND FORTIFY¹

CROHN’S DISEASE THERAPIES EVALUATED
IN AN OPEN-LABEL ASSESSOR BLINDED HEAD-TO-HEAD TRIAL^2,3

HEAD-TO-HEAD TRIAL: PRIMARY ENDPOINTS (NRI-MI)^2,3

ENDOSCOPIC OUTCOMES^2,3

ENDOSCOPIC OUTCOMES^2,3

ENDOSCOPIC OUTCOMES^2,3

SYMPTOM RELIEF DATA^2,3

SAFETY PROFILE: EVALUATION THROUGH WEEK 48^2,3

HEAD-TO-HEAD OPEN-LABEL TRIAL DESIGN^1-3

Phase 3, Multicenter, Randomized, efficacy-assessment blinded, treat-through study comparing SKYRIZI and STELARA (ustekinumab) in adult patients with moderate to severe Crohn's disease who have failed anti-TNF therapy

BASELINE CHARACTERISTICS^1-3

SEQUENCE

SKYRIZI
N=255

FORTIFY

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

An extensive Phase 3 clinical program in Crohn’s Disease
1,419 PATIENTS ENROLLED ACROSS SKYRIZI TRIALS

Phase 3 Clinical program: Study Design Details^1-5

ADVANCE
N=850

MOTIVATE
N=569

FORTIFY
N=382

Phase 3 clinical program: baseline characteristics^1,2

ADVANCE

Placebo

SKYRIZI 600 mg IV

MOTIVATE

Placebo

SKYRIZI 600 mg IV

FORTIFY

Placebo
(Induction Responder)

SKYRIZI
180 mg SC

SKYRIZI
360 mg SC

FORTIFY

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

SKYRIZI vs STELARA® (ustekinumab) RESULTS FROM A HEAD-TO-HEAD STUDY

ENDPOINTS IN ADVANCE, MOTIVATE AND FORTIFY1

CROHN’S DISEASE THERAPIES EVALUATED IN AN OPEN-LABEL ASSESSOR BLINDED HEAD-TO-HEAD TRIAL2,3

HEAD-TO-HEAD TRIAL: PRIMARY ENDPOINTS (NRI-MI)2,3

ENDOSCOPIC OUTCOMES2,3

ENDOSCOPIC OUTCOMES2,3

ENDOSCOPIC OUTCOMES2,3

SYMPTOM RELIEF DATA2,3

SAFETY PROFILE: EVALUATION THROUGH WEEK 482,3

SEQUENCE

SKYRIZI N=255

FORTIFY

Placebo (Induction Responder) N=164

SKYRIZI 360mg SC N=141

ADVANCE N=850

MOTIVATE N=569

FORTIFY N=382

ADVANCE

Placebo

SKYRIZI 600 mg IV

MOTIVATE

Placebo

SKYRIZI 600 mg IV

FORTIFY

Placebo (Induction Responder)

SKYRIZI 180 mg SC

SKYRIZI 360 mg SC

FORTIFY

Placebo (Induction Responder) N=164

SKYRIZI 360mg SC N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1

SKYRIZI vs STELARA^® (ustekinumab)
RESULTS FROM A HEAD-TO-HEAD STUDY

ENDPOINTS IN ADVANCE, MOTIVATE AND FORTIFY¹

CROHN’S DISEASE THERAPIES EVALUATED
IN AN OPEN-LABEL ASSESSOR BLINDED HEAD-TO-HEAD TRIAL^2,3

HEAD-TO-HEAD TRIAL: PRIMARY ENDPOINTS (NRI-MI)^2,3

ENDOSCOPIC OUTCOMES^2,3

ENDOSCOPIC OUTCOMES^2,3

ENDOSCOPIC OUTCOMES^2,3

SYMPTOM RELIEF DATA^2,3

SAFETY PROFILE: EVALUATION THROUGH WEEK 48^2,3

SKYRIZI
N=255

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

ADVANCE
N=850

MOTIVATE
N=569

FORTIFY
N=382

Placebo
(Induction Responder)

SKYRIZI
180 mg SC

SKYRIZI
360 mg SC

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹